Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Insmed Inc (NASDAQ:INSM)

During the Trading Day
17.43 +0.31 / +1.81%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
17.43 +0.0035 / +0.02%
Volume: 3.6K
Health Technology

Company Description

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The company is focused on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Its main product ARIKAYCE or LAI, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. Insmed was founded on November 29, 1999 and is headquartered in Monmouth Junction, NJ.

Contact Information

Insmed, Inc.
Building 10
Bridgewater New Jersey 08807-3365
P:(908) 977-9900
Investor Relations:



Individual stakeholders5.06%
Mutual fund holders47.53%
Other institutional41.48%

Top Executives

William H. LewisPresident, Chief Executive Officer & Director
Andrew T. DrechslerChief Financial Officer
Walter R. PerkinsChief Technology Officer
Gina EagleVice President-Clinical Research
Eugene Jeffrey SullivanChief Medical & Scientific Officer